For years, researchers faced a major problem: vaccinating the body was not enough to protect the area attacked by the virus. Akiko Iwasaki’s team chose another strategy: prepare immunity, then bring it precisely to where the infection begins.
Genital herpes, a discreet infection but with profound consequences
Genital herpes is a common disease, but still largely shrouded in silence. According to the World Health Organization, approximately 42 million people become infected with the genital herpes virus each year.
Once established in the body, the herpes simplex virus type 2 (HSV-2) generally remains for life. Current treatments help reduce flare-ups and symptoms, but they do not cure the infection or always prevent its transmission.
Beyond the physical manifestations – pain, lesions, recurrences – the psychological impact can be considerable. Fear of being looked at by others, guilt or worry in their intimate lives are often part of the daily lives of those affected.
It is in this context that a team from the Yale School of Medicine is exploring a new vaccine avenue, published in 2026 in the journal Science Immunology.
A two-step strategy for placing defenses in the right place
The challenge of herpes vaccines is unique. A classic injection into the muscle does indeed result in a general immune response, but it hardly creates strong protection at the level of the vaginal mucosa, where the virus enters the body.
The researchers therefore imagined an approach called “prime-and-pull”:
- The first step, the “prime”, consists of a classic intramuscular injection which prepares the immune system by creating defense cells capable of recognizing the virus;
- The second, the “pull”, consists of attracting these cells directly to the threatened area using nanoparticles called BEACON applied locally in the vagina.
The image used by the researchers is simple: train the army in a training center, then deploy it exactly on the border where the enemy is likely to attack.
“Our preclinical experiments have demonstrated that this approach safely recruits the right immune cells to the right location to generate protective immunity.”explains Akiko Iwasaki, professor of immunobiology at Yale School of Medicine.
In mice, protection that lasts at least six months
To create these BEACON nanoparticles (Bioactive Enhanced Adjuvant Chemokine Oligonucleotide Nanoparticles), the researchers combined two elements: a DNA fragment capable of stimulating immunity and a molecule called CXCL9a chemokine that acts as a calling signal for certain immune cells.
Their objective: to attract the right defenses without causing excessive inflammation. In the study, female mice first received an intramuscular herpes vaccination, and then BEACON nanoparticles combined with viral antigen were applied topically.
The results were striking: this strategy made it possible to create a strong presence of resident immune cells in the tissues and to produce antibodies IgG and IgA
in the vaginal mucosa for at least six months.
When the mice were then exposed to the virus, 80% of animals vaccinated with this approach remained without signs of diseaseagainst Only 40% among those who received the intramuscular injection alone.
“This showed us that this approach could have a profound impact, establishing local immune responses for a significantly long period of time. “, explains Sachin Bhagchandani, postdoctoral researcher in Akiko Iwasaki’s team and first author of the study.
A promise for patients, but not yet a human vaccine
This discovery represents an important advance, but it remains at the preclinical stage. The results obtained in mice will need to be confirmed before considering trials in humans. Researchers are now working to transform BEACON into a form suitable for human use, particularly in the form of a vaginal suppository. They are also exploring a nasal route that could make it possible to adapt this strategy to men.
The team also wants to know if this method could be of interest not only in preventing infection, but also in limiting reactivations in people already carrying the virus.
For Akiko Iwasaki, the issue goes far beyond just the biology of the virus.
“Much of the suffering patients endure is not just physical; it is also mental and social”she recalls. “But viruses are the same — whether it’s the flu, the Epstein-Barr virus, or herpes simplex, it’s not the person’s fault that they caught it. However, there is a lot of stigma. We hope that this type of strategy will help prevent diseases that profoundly affect people.”.
Towards a new generation of vaccines: protecting where it all begins
The benefit of this approach perhaps goes beyond genital herpes. It illustrates an evolution in vaccinology: no longer seeking only to strengthen general immunity, but learning to install defenses directly in exposed tissues.
For the millions of people affected by genital herpes, the hope is not yet that of a treatment available tomorrow. But this research brings a new perspective: that of a vaccine capable of blocking the virus before it can even take hold.
A different way of imagining prevention: no longer just responding to infection, but preventing it from starting.